Real-World Study Finds Oral Combination Therapy of Macitentan, Riociguat, and Selexipag Effective in PAH
March 02, 2021 10:45pm
Triple oral combination therapy with macitentan, riociguat, and selexipag may be a promising strategy to treat patients with low/intermediate-risk pulmonary arterial hypertension (PAH), and possibly even patients with high-risk PAH.